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Abstract: In vitro experimentation provides a convenient controlled environment for testing biological hypotheses of 
functional genomics in cancer induction and progression. However, it is necessary to validate resulting gene signatures from 
these in vitro experiments in human tumor samples (i.e. in vivo). We discuss the several methods for integrating data from 
these two sources paying particular attention to formulating statistical tests and corresponding null hypotheses. We propose 
a classiﬁ  cation null hypothesis that can be simply modeled via permutation testing. A classiﬁ  cation method is proposed 
based upon the Tissue Similarity Index of Sandberg and Ernberg (PNAS, 2005) that uses the classiﬁ  cation null hypothesis. 
This method is demonstrated using the in vitro signature of Core Serum Response developed by Chang et al. (PLoS Biology, 
2004).
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Introduction
Integration of in vitro studies, i.e. experimental studies, with human “in vivo” gene expression studies 
is an area that is being considered more frequently in the functional genomic analysis of cancer. Hypoth-
eses about cancer development, progression, and risk factors are difﬁ  cult to test directly in a patient 
population. However, in experimental studies on cell cultures and model organisms, conditions can be 
speciﬁ  cally controlled to allow biological hypotheses to be tested. Integrating the results from such 
experiments with in vivo cancer signatures holds the potential to both infer activity of speciﬁ  c oncogenic 
pathways in vivo and to identify relevant effectors of oncogenic pathways. 
To begin to understand the mechanisms by which oncogenes cause cancer, studies have used gene-
expression proﬁ  ling to identify downstream targets of oncogenic pathways in cell-culture systems. 
Conceptually, this involves manipulating a gene in an in vitro system, measuring the global proﬁ  le using 
gene expression technology and then trying to relate the in vitro gene expression proﬁ  le to an in vivo 
gene expression proﬁ  le. Such an approach was taken by Lamb et al. (2003) to determine the direct 
transcriptional effects of the oncogene Cyclin D1. In vitro experiments were performed in which the 
Cyclin D1 was both over and under expressed, and global gene expression proﬁ  les were determined. 
Lamb et al. (2003) found that there was a signiﬁ  cant correlation between the targets found in vitro and 
the ordered gene list in a human tumor dataset thus suggesting the role of Cyclin D1 regulation in 
tumorigenesis, another example of in vitro/in vivo gene expression data integration appears in the study 
of Huang et al. (2003). They developed distinct in vitro oncogenic signatures for three transcription 
factors: Myc, Ras and E2F1-3. These signatures were able to predict the Myc and Ras state in mammary 
tumors that developed in transgenic mice expressing either Myc or Ras, suggesting that speciﬁ  c onco-
genic events are encoded in global gene-expression proﬁ  les.
Additionally, studies have used gene-expression proﬁ  ling of cancerous growths induced in model 
organisms to examine tumor development or progression. Though model organism studies have the 
added difﬁ  culty of mapping orthologous genes between organisms, a difﬁ  culty not shared with tissue 
and cell cultures of human origin, there have been promising applications. For example, Sweet-Cordero 
et al. (2005) deﬁ  ned a KRAS induced lung cancer signature by comparing lung tumors generated from 
a spontaneous KRAS mutation mouse model to normal mouse lung tissue. They then correlated this 
KRAS lung cancer signature with gene expression proﬁ  les in human lung cancer studies and found that 
the mouse signature shared signiﬁ  cant similarity with human lung adenocarcinoma but not with other Cancer Informatics 2007:3 232
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lung cancer types. Next, Sweet-Cordero et al. 
(2005) looked for evidence of the KRAS signature 
in human tumors carrying activating KRAS muta-
tions relative to wild-type tumors. Although no 
individual genes were signiﬁ  cantly associated with 
the KRAS mutation status in human tumors, the 
mouse KRAS signature was signiﬁ  cantly enriched 
among genes rank-ordered by differential expres-
sion in human tumors with a KRAS mutation. 
It is expected that in vitro/in vivo experiments such 
as those described in the previous two paragraphs will 
become much more commonplace in the future. Thus, 
it is critical to address statistical issues and to develop 
methods for integrating in vivo and in vitro genomic 
data so that inferences regarding transcriptional regu-
latory pathways in cancer can be generated. In this 
article, we discuss the statistical issues of the integra-
tion of these two types of datasets. We review various 
existing approaches and discuss their statistical advan-
tages and disadvantages. In addition, we outline an 
approach for quantifying the predictive ability of a 
gene expression proﬁ  le determined from an in vitro 
experiment based on the tissue similarity approach of 
Sandberg and Ernberg (2005). We describe the appli-
cation of the proposed methodology using in vitro 
data from a wound healing study conducted by Chang 
et al. (2004) and in vivo data from Glinsky et al. 
(2004), van’t Veer et al. (2002), and Beer et al. (2002). 
Finally, we conclude with some discussion. 
Background and Review
One class of methods that has been popular in the 
literature for in vitro/in vivo genomic data analysis 
is the following. First, one generates ordered lists 
of genes using the in vivo expression data. One 
then generates a differentially expressed gene list 
using the in vitro data and studies the overlap 
between the two lists. The seminal examples of 
this are in Mootha et al. (2003) and Lamb et al. 
(2003), which were then used as the basis of the 
Gene Set Enrichment Analysis (GSEA) method 
(Subramanian et al. 2005). We describe the GSEA 
methodology by brieﬂ  y reviewing what was done 
in the Lamb et al. (2003) study. First, a list of 
differentially expressed genes was generated based 
on the comparison of Cyclin D1 overexpressing 
relative to wildtype (no Cyclin D1 manipulation) 
mammary epithelial cell lines. Next, each gene’s 
expression in vivo, from 190 human tumor samples 
of various origins, was correlated to that of Cyclin 
D1 and the genes were ranked accordingly. Then, 
a Kolmogorov-Smirnov (KS) statistic was used to 
determine if the in vitro differential expression list 
clustered within the correlation-ordered in vivo 
list. Since there was signiﬁ  cant evidence of clus-
tering, Lamb et al. (2003) determined that the in 
vitro-deﬁ  ned targets of Cyclin D1 were correlated 
with their respective levels in vivo. This suggests 
that the direct regulatory effects of Cyclin D1 may 
play an important role in tumorigenesis. 
There are some desirable features of the GSEA 
method. First, it utilizes all the information available 
in the in vivo gene expression data; no thresholding 
is done in that dataset. Second, a Kolmogorov-
Smirnov statistic is used for the analysis, which is 
a non-parametric method and thus provides some 
robustness. However, there are several disadvan-
tages to GSEA as well. For instance, note that there 
is thresholding done in the in vitro gene expression 
dataset to select the differentially expressed gene 
set. A potential improvement to the GSEA method, 
to avoid this thresholding, would be the following. 
First, one determines the common genes in the in 
vivo and in vitro datasets. One then takes the scores 
of differential expression from the in vitro data, ﬁ  nds 
the corresponding correlation scores (correlation 
with Cyclin D1) in the in vivo data and examines a 
scatterplot of the two variables. If the association is 
linear, then one tests for association using the 
Pearson correlation coefﬁ  cient between the two 
variables. If instead the association appears 
nonlinear, then one could use a smoothing-spline 
based test (Lin, 1997). Such an approach would give 
a direct test of association between the correlations 
in vivo and the differential expression measurement 
in vitro without requiring thresholding of any data-
sets and would still allow for a nonlinear relationship 
between the two variables. 
Before going further, let us consider the null 
hypothesis under consideration in the GSEA 
method, or the variants proposed above. Speciﬁ  -
cally, in the Lamb et al. (2003) study they test: 
H0: There is no association between 
differential expression of Cyclin 
D1-overexpressed, relative to non-
overexpressed, cell lines and correlation 
with Cyclin D1 in human tumors
The alternative hypothesis is that there is an asso-
ciation. In specifying the null hypothesis we 
uncover a more subtle disadvantage of the GSEA Cancer Informatics 2007:3 233
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method—the determination of the distribution of 
the KS test statistic under the null hypothesis. Two 
variants of permutation testing have been proposed 
by Subramanian et al. (2005) to elucidate the 
distribution of the KS test statistic assuming the 
null hypothesis is true. In the ﬁ  rst, the sample labels 
in the in vitro data are permuted, the differentially 
expressed gene signature is redeﬁ  ned, and the 
Kolmogorov-Smirnov statistic is recomputed 
based on this new signature; see Figure 1a, red. 
Here the implication is that the correlation between 
the two Cyclin D1 levels in the cell line experiment 
is removed by the permutation. However, this 
addresses the differential expression in the in vitro 
samples but does not address a null association 
with the in vivo samples. In the second version, 
the sample labels in the in vitro and in vivo datasets 
are permuted, both the in vitro differential expres-
sion signature and the in vivo correlations are 
redeﬁ  ned, and the Kolmogorov-Smirnov statistic 
is recomputed; see Figure 1a, blue. Again, the 
implication is to remove the association within the 
in vitro and in vivo experiments. Yet this permuta-
tion scheme still does not address the association 
between the in vitro differential expression and the 
in vivo correlation. The role of permutation testing 
is to simulate the distribution of the test statistic 
assuming that H0 is true; however, the two permu-
tation schemes developed in the GSEA method do 
not do this. Permutation of the sample labels fails 
because the null hypothesis pertains to the popula-
tion of genes in the two studies and not the relation 
of samples within a study. Additionally, Shedden 
(2004) suggests that permuting the sample labels 
of both the in vitro and in vivo data sets is not 
appropriate. Simply, if the permutation does not 
correctly model the null hypothesis correctly, then 
we are answering a different question than the one 
asked. 
There is an alternative approach to the GSEA 
method for integrative analysis of in vitro and 
in vivo data, which is what we focus on in the 
rest of the paper. It is based on ideas of classi-
fication and clustering since the goal in many 
genomic studies utilizing high-throughput 
expression technologies is to develop a signa-
ture that can discriminate between relevant 
classes or groups of samples. In general, demon-
stration of the predictive or prognostic ability 
of a classification signature on independent data 
sets is a crucial step in the validation of that 
signature (Ransohoff, 2004). Thus, differential 
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Figure 1. Schematic representations of the GSEA-type and TSI-type algorithms. (A) The GSEA-type algorithm is depicted along with the 
two suggested permutation tests (red = permutation 1, blue = permutation 2). Details of the Lamb et al. (2003) study are included for illustra-
tion. (B) The TSI-type algorithm is depicted along with the suggested permutation test (red). Details of the Chang et al. (2004) Core Serum 
Response signature classiﬁ  cation are included for illustration. Cancer Informatics 2007:3 234
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expression signatures discovered in vitro are 
often “validated” on independent in vivo data 
sets, such that the in vitro data is the training 
dataset and the in vivo data is the testing dataset. 
In this validation setting, the null hypothesis 
that we wish to test is the following:
H0
class: There exists no set of genes 
derived from the in vitro gene expression 
dataset that can predict clinical outcome 
in the in vivo expression data
The alternative is that at least one set of genes 
derived from the in vitro data is predictive. Notice 
that this null hypothesis is different from the null 
hypothesis described for the GSEA method. For 
clarity, we will refer to H0
class as the classiﬁ  cation 
null hypothesis.
An advantage of the classiﬁ  cation null hypoth-
esis is that permutation testing becomes possible 
here. In particular if H0
class is true, then any set of 
genes derived from the in vitro expression proﬁ  le 
data will have no ability to separate samples in the 
in vivo expression dataset with regard to a clinical 
outcome. Thus, we can take random sets of genes 
from the in vitro data and apply the classiﬁ  cation 
algorithm of interest. If the classiﬁ  cation null 
hypothesis is true, then all sets of genes, including 
the derived signature, should provide equal predic-
tion performance.
The classiﬁ  cation null hypothesis has motivated 
the following algorithm that we have used in our 
previous work (Varambally et al. 2005). Here we 
are considering the genes common to the in vitro 
and in vivo expression datasets.
1. Derive a gene signature from the in vitro gene 
expression data; 
2. Select those genes from the in vivo expression 
data that are included in the in vitro signature 
and cluster the samples from the in vivo expres-
sion data into two groups using hierarchical 
clustering with average linkage clustering and 
Euclidean distance;
3. Calculate the log-rank statistic for survival 
between the two groups of patients;
4. Let L denote the size of the gene list in 1. Ran-
domly choose L genes from the in vitro data as 
the gene signature. Continue with steps 2 and 
3 above. 
5. Repeat steps 2–4 1000 times. Calculate the 
proportion of datasets in which the log-rank 
statistic is greater than the one calculated ini-
tially from the signature in step 1.
The proportion calculated in step 5 will be the 
permutation p-value under the classiﬁ  cation null 
hypothesis. This permutation scheme will form the 
basis of assessing signiﬁ  cance for our proposed 
analytical scheme described in the next section. 
We note that one could also modify the GSEA 
procedure in a similar way, as shown in Lamb et al. 
(2003), such that we randomly draw the gene set 
from the in vitro data rather than assessing differ-
ential expression based on permuted sample labels. 
Unfortunately, Shedden (2004) shows that when 
one does not account for gene-gene correlation, 
the resulting test statistic can be too liberal by as 
much as 10 times.
Notice that a limitation of the classiﬁ  cation null 
hypothesis is that the alternative hypothesis states 
that there exists at least one signature from the 
in vitro expression data that is predictive in the 
in vivo expression data. In fact the experimentally 
derived gene list need not be a unique classiﬁ  er. It 
has been recently noted that there are likely many 
gene signatures that have similar predictive power 
(Ein-Dor et al. 2005; Fan et al. 2006). It may be 
due in part to genetic redundancy or to the high 
correlation of genes within a pathway. Yet if the 
in vitro gene signature is able to predict prognosis 
better than a randomly selected set of genes we 
expect that there is biological signiﬁ  cance to that 
signature. Thus permutation testing helps us to 
determine if the gene set derived from the in vitro 
experiments is of interest for further study of its 
biological relevance.
Proposed methodology for in vitro/
in vivo analyses
The paper of Sandberg and Ernberg (2005) 
considers the relationship between the gene expres-
sion of in vitro cell cultures and their respective in 
vivo tumor samples. To that end they developed 
an algorithm for comparing gene expression values 
across experiments that they call the tissue simi-
larity index (TSI). We use that algorithm here to 
compare the in vivo tumor samples to the in vitro 
samples of a lab experiment. 
The algorithm of Sandberg and Ernberg (2005) 
is as follows; see Figure 1b. Principal component 
analysis is run on the covariance matrix of gene 
expression for genes in the in vitro dataset. Data Cancer Informatics 2007:3 235
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are scaled across arrays so that each gene has a 
mean expression of zero and a unit standard 
deviation. The resulting eigenarrays (eigenvectors) 
are stored. To project the in vitro gene expression 
into the reduced dimensional space, created by the 
eigenarrays, calculate the correlation between each 
eigenarray and each in vitro sample array. The 
consensus signature for each experimental condi-
tion (serum induced and serum independent) is 
represented by its median centroid in the reduced 
space.
To integrate the in vivo data, ﬁ  rst map the in 
vivo samples into the same reduced space of the 
in vitro samples by again calculating the correlation 
between each eigenarray and in vivo sample array. 
To maintain scale in this correlation, the tumor 
samples are also standardized so that each gene 
has a mean expression of zero and a unit standard 
deviation. The distance between the in vivo tumor 
sample and each of the two consensus signatures, 
i.e. centroids, is calculated using Pearson correla-
tion. Samples are classiﬁ  ed with the experimental 
condition with whose centroid they correlate 
best. 
There are several differences between their and 
our implementations of TSI. First, in contrast to 
Sandberg and Ernberg (2005), we use positive 
statistical signiﬁ  cance of the TSI to determine 
classification, thus allowing some samples to 
remain unclassiﬁ  ed. In their paper they used an 
ad-hoc threshold value for TSI score, delineating 
moderate and high correlation groups. It is natural 
to believe that some of the in vivo samples will not 
correlate well with the in vitro conditions. These 
unclassiﬁ  ed samples may actually be informative 
in that they deﬁ  ne a subset of cases which do not 
meet our expectation as developed in the hypoth-
eses tested in vitro. Second, the goal of the Sand-
berg and Ernberg (2005) paper was qualitative 
assessment of cell line gene expression relative to 
in vivo tumor gene expression, thus they do not 
address the issue of statistical signiﬁ  cance of their 
method. However, the classiﬁ  cation provided by 
the TSI can be tested for prognostic or diagnostic 
value depending upon the study goal.
Since the gene signature on which the classiﬁ  ca-
tion is based is determined from the in vitro data, 
and does not use the in vivo data, the statistical 
signiﬁ  cance of any tests on the in vivo data can be 
accepted without bias. This is an example of using 
the in vitro data for the training dataset and the in 
vivo data for the testing dataset. Indeed, if this in 
vivo validation is not at least marginally signiﬁ  cant 
it is not of interest to proceed further to test the 
classiﬁ  cation null hypothesis. 
Using the TSI method, we develop a classiﬁ  ca-
tion scheme from the in vitro signature. The null 
hypothesis of interest is again the classiﬁ  cation 
null hypothesis as presented above. We thus 
propose the use of a permutation test to determine 
the utility of the gene signature in its classiﬁ  cation 
ability. In the following we slightly modify the 
permutation test procedure described in the 
previous section to account for gene-gene correla-
tion within the in vitro gene signature. Speciﬁ  cally, 
as it is likely that genes within a pathway are corre-
lated, it is reasonable to assume that the signiﬁ  -
cantly differentially expressed genes that comprise 
the in vitro signature are correlated. Shedden, 
(2004) showed that this correlation can lead to 
invalid p-values. In the classical genetics setting, 
Nyholt, (2004) shows that permutation tests that 
do not account for this correlation can be misleading 
and proposes a simple adjustment. In essence, 
rather than randomly selecting L genes in each 
cycle of the permutation test, only M (M   L) 
genes are selected, where M is calculated to be the 
effective number of independent genes in the gene 
signature (Nyholt, 2004); see Figure 1b. 
Finally, the permutation test for the TSI analysis 
has two interesting attributes against which the 
classiﬁ  cation signature is compared. Speciﬁ  cally, 
in permuting the data, the TSI scores are recalcu-
lated using the randomly selected gene list and with 
each randomly selected set of genes there is a 
possibility of unclassiﬁ  ed samples. Thus the clas-
siﬁ  cation is compared to: (1) the measure of asso-
ciation with predictive factors in vivo, and (2) the 
percentage of unclassiﬁ  ed samples in vivo. 
Results
Data acquisition and preparation
For the purpose of demonstration we use, as the 
in vitro derived signature, the wound healing 
signature of Chang et al. (2004). Derived from 
cultured ﬁ  broblasts in the presence and absence of 
serum components, the wound healing signature is 
composed of 573 genes that are differentially 
expressed in response to serum. We consider the 
wound healing signature, or Core Serum Response 
(CSR), as the in vitro basis of classiﬁ  cation of in 
vivo tumor samples—prostate tumor samples Cancer Informatics 2007:3 236
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(Glinsky et al. 2004), breast tumor samples (van’t 
Veer et al. 2002), and lung tumor samples (Beer 
et al. 2002)—into good and bad prognosis groups. 
The ﬁ  broblast gene expression data (Chang et al. 
2004) was downloaded from the Stanford Micro-
array Database (SMD, http://smd.stanford.edu/
cgi-bin/publication/viewPublication.pl? pub_
no=293) (platform: cDNA microarray, 50 samples). 
The data were normalized using loess normalization 
by print block within array (Yang et al. 2002). Inter-
array variability was accounted for by scaling using 
the MAD (median absolute deviation). Missing data 
was imputed using KNN (K-nearest neighbors) 
imputation as implemented in the pam.r package 
(Hastie et al. 1999; Troyanskaya et al. 2001).
Localized prostate tumor probe-set level expres-
sion measures and recurrence free survival infor-
mation (Glinsky et al. 2004) were obtained from 
the Sidney Kimmel Cancer Center website (no 
longer posted at time of submission) (platform: 
Affymetrix U95Av2, 295 samples). Lung adeno-
carcinoma probe-set level expression measures and 
overall survival information (Beer et al. 2002) were 
obtained from http://dot.ped.med.umich.edu:2000/
pub/Lung/index.html (platform: Affymetrix 
HUgenFL, 86 samples). Sporadic breast cancer 
expression data and recurrence free survival infor-
mation (van’t Veer et al. 2002) were obtained from 
http://www.rii.com/publications/2002/vantveer.
html (platform: Aglient Hu25K, 78 samples). Each 
of these experiments was normalized by global 
scaling per array. No imputation was done for 
missing data in the tumor sample data sets. 
Unigene Cluster ID number was used to map genes 
between platforms. Annotation information was 
acquired from SOURCE (Diehn et al. 2003). If, for a 
given platform, multiple measurements were repre-
sented by the same Unigene Cluster ID, these expres-
sion values were averaged within array, thus allowing 
one-to-one mapping of genes between platforms. 
Genes were mapped to Unigene Cluster ID from 
GenBank Accession number if available (Chang et al. 
2004; Glinksy et al. 2004; van’t Veer et al. 2002) or 
from Unigene Symbol (Beer et al. 2002)
Application of the TSI based 
classiﬁ  er
The classiﬁ  er was built using the CSR in vitro 
signature and the TSI algorithm, described in the 
previous section and in Figure 1b. The classiﬁ  er was 
built for each of the three in vivo experiments using 
only those genes in the CSR signature that were 
common to both the in vivo and in vitro experiments; 
see Table 1 and Figure 2. All 50 eigenarrays were 
used for the TSI classiﬁ  cation algorithm and clas-
siﬁ  cation is based on signiﬁ  cant positive correlation 
with one of the two CSR group centroids. Figure 3 
plots the ﬁ  rst two dimensions of this reduced space 
for each of the three tumor types. The cell cultures 
that were grown in the presence of serum were 
considered to be serum induced, whereas those 
grown without serum components were serum 
independent. In vivo samples that correlate signiﬁ  -
cantly (p < 0.05) with the composite serum induced 
signature, i.e. centroid, are classified as serum 
induced. Likewise, those in vivo samples correlating 
signiﬁ  cantly with the centroid of the serum inde-
pendent samples are labeled serum independent. In 
vivo samples that do not correlate signiﬁ  cantly with 
either centroid remain unclassiﬁ  ed. In Figure 3, the 
tumor samples are colored according their classiﬁ  -
cation and the in vitro samples and centroids are 
included for reference. 
According to H0
class, we wish to see if the in vitro 
derived CSR signature has prognostic ability in vivo. 
Table 1. Genes were matched between platforms using Unigene ID numbers. For the permutation testing, all 
common genes between the in vitro experiment (Chang et al. 2004) and each in vivo experiment were considered 
(prostate: Glinsky et al. 2004; breast: van’t Veer et al. 2002; lung: Beer et al. 2002). The classiﬁ  cation of a set of 
in vivo samples was done based on only the CSR genes identiﬁ  ed in that data set. Permutation sample size was 
determined based on the effective number of independent genes in the CSR signature.
  Unigene maped  Genes common  Unigene  Effective number
  genes per  with in vitro  mapped  of independent
 microarray  samples  CSR  genes  genes
In Vitro Samples  20414  —  484  —
Prostate Cancer Samples   11772  9753  367  345
Breast Cancer Samples  17168  13600  421  399
Lung Cancer Samples   4705  3891  158  136Cancer Informatics 2007:3 237
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Thus the prognostic ability of the CSR signature as 
a classiﬁ  er was tested using univariate Cox regres-
sion; see Table 2. The TSI score was incorporated 
through its discrete classiﬁ  cation of the in vivo 
samples, as described above. Figure 4 contains the 
Kaplan-Meier survival curves for this discrete clas-
siﬁ  cation. The red and blue curves represent the 
serum activated and serum independent classiﬁ  ca-
tions, respectively. Log-rank statistics on the 
Kaplan-Meier estimates indicate that there is a 
signiﬁ  cant separation between the curves for the 
prostate tumors (p < 0.0001), the breast tumors 
(p = 0.0207), and the lung tumors (p = 0.0352). The 
tan curve shows the survival of those samples that 
did not signiﬁ  cantly correlate with either the serum 
activated or serum independent proﬁ  les and are thus 
left unclassiﬁ  ed by the TSI algorithm. When this 
unclassiﬁ  ed group was included in the Log-rank test 
of survival curve separation the prostate cancer and 
breast cancer samples remained significant 
(p < 0.0001 and p = 0.0078, respectively) whereas 
the lung cancer samples were marginally signiﬁ  cant 
(p = 0.0789).
Permutation testing of H0
class
Accepting the above signiﬁ  cant separation of the 
Kaplan-Meier curves as validation of the CSR 
signature in vivo, we proceed to test the classiﬁ  ca-
tion null hypothesis using 1000 random samples 
A BC D
Figure 2. Heatmap of core serum response genes in each of the four data sets considered. Red are serum induced samples, blue are serum 
independent samples, and tan are unclassiﬁ  ed samples. (A) Expression of 484 Unigene mapped core serum response genes in the 50 in 
vitro samples of the primary experiment (Chang et al. 2004). (B) Expression of the 376 core serum response genes in the 295 prostate tumor 
samples (Glinsky et al. 2004) (C) Expression of the 421 core serum response genes in the 78 van’t Veer samples (van’t Veer et al. 2002) 
(D) Expression of the 158 core serum response genes in the 86 Beer samples (Beer et al. 2002).Cancer Informatics 2007:3 238
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from the genes in common between the in vivo and 
in vitro samples, see Table 1. The size of the 
randomly drawn set of genes was determined by 
the correlation in the original CSR genes, such that 
the randomly drawn sets contained an equivalent 
number of effectively independent genes as the 
CSR set. The TSI score was recalculated on each 
of these 1000 random gene sets. It was then used 
to classify the in vivo samples and predict survival. 
Figure 5 depicts the classiﬁ  cation and prediction 
ability of the 1000 random sets for each of the three 
in vivo data sets. The CSR gene predictor is colored 
red in these plots. The vertical axis plots the predic-
tive ability of the gene set as the chi-squared test 
statistic associated with univariate Cox regression 
on the classiﬁ  er. If we look at the vertical margin 
we arrive at the permutation p-value as depicted 
by the marginal histogram. However, we have 
additional information about the utility of the CSR 
signature as a classifier. The horizontal axis 
provides the percentage of the samples that 
remained unclassiﬁ  ed in each of the 1000 random 
sets. In each case, the classiﬁ  er based on the CSR 
genes has a lower percentage of unclassified 
samples than any of the randomly drawn gene sets. 
Finally, note that for some of the randomly drawn 
gene sets, see Figures 5B and 5C, the samples were 
classiﬁ  ed into only one group and thus the chi-
squared test statistic could not be calculated. This 
occurred when the percentage of unclassified 
samples was high. 
Discussion
TSI based classiﬁ  cation shows 
heterogeneity among samples
As depicted in Figure 2, the simple dichotomiza-
tion of in vivo samples by hierarchical clustering 
is far from optimal. By the nature of hierarchical 
clustering, dichotomization can be achieved by 
splitting samples at the ﬁ  rst node. In Figure 2 we 
have color coded the samples by their TSI predicted 
classiﬁ  cation (red = serum activated, blue = serum 
independent, tan = unclassiﬁ  ed) and we see that 
there is heterogeneity in the classiﬁ  cation suggested 
by dichotomization at the ﬁ  rst node of the dendro-
gram. This heterogeneity is apparent in the Kaplan 
Meier plots of Figure 4. Notice that the prostate 
samples appear to be least heterogeneous, see 
Figure 2B, in that most of the serum activated 
samples are clustered on the left and most of the 
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Figure 3. In vitro samples and tumor samples are plotted for the ﬁ  rst 
two dimensions of the reduced space. (A) 55% of the prostate tumor 
samples are classiﬁ  ed: 78 as serum induced, 83 as serum indepen-
dent  (B) 69.3% of the breast tumor samples are classiﬁ  ed: 27 as 
serum induced, 27 as serum independent. (C) 48.9% of the lung 
tumor samples are classiﬁ  ed: 18 as serum induced, 24 as serum 
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Figure 4. Survival of classiﬁ  ed tumor samples demonstrating that patients with samples in the serum induced class are likely to have a 
worse prognosis. Both the classiﬁ  ed and unclassiﬁ  ed samples are included in these plots. The log-rank statistic p-values from Kaplan 
Meier estimation are given for the separation of the classes without and with inclusion of the unclassiﬁ  ed samples (A) recurrence free sur-
vival in prostate cancer: p < 0.0001; p < 0.0001, (B) recurrence free survival in breast cancer: p = 0.0207; p = 0.0078, (C) overall survival in 
lung cancer: p = 0.0352; p = 0.0789.Cancer Informatics 2007:3 240
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serum independent samples are clustered on the 
right with the unclassiﬁ  ed samples interspersed 
among both branches. The Kaplan Meier plot in 
Figure 4A suggests that those samples which can 
be classiﬁ  ed by their serum response have the best 
and worst recurrence free survival with the unclas-
siﬁ  ed samples having intermediate recurrence free 
survival. The intermediate nature of the unclassi-
ﬁ  ed samples may be due to a third class of tumors 
with moderate serum response or it may be due to 
a blending of high risk and low risk samples that 
were not separated by the CSR signature. 
The breast cancer samples appear to have a more 
well deﬁ  ned subset of unclassiﬁ  ed samples, see 
Figure 2c. The far right branch of the dendrogram 
(as split on the second node) contains a high 
percentage of unclassiﬁ  ed samples. In the Figure 
4b, the unclassiﬁ  ed samples are associated with a 
recurrence free survival curve that is worse than 
for the serum activated samples. In the lung cancer 
data it is not clear that classiﬁ  cation on any of the 
ﬁ  rst three nodes of the dendrogram would result 
in homogeneous classiﬁ  cation based on the CSR 
signature; see Figure 2d. However, using the TSI 
classiﬁ  cation we are able to signiﬁ  cantly split the 
samples into good and bad prognosis groups based 
on overall survival; see Figure 4c.
Differences in array conﬁ  gurations 
may reduce utility of the in vitro 
signature
One problem encountered in this analysis was the 
integration of gene expression data across micro-
array platforms. We attempted to compensate for 
this numerically by global standardization that 
centered the array-wise median values at zero. 
Furthermore, in the TSI algorithm genes were stan-
dardized to zero mean and unit standard deviation 
before being mapped into the reduced space. An 
additional complication, beyond numerical scaling, 
is that the differing array conﬁ  gurations between the 
in vitro and in vivo experiments mean that only those 
genes with Unigene ID numbers common to both 
data sets can be considered. This initially excludes 
ESTs from the in vitro signature as well as other 
features that do not have Unigene ID numbers. The 
signature is further reduced by focusing on only the 
common genes between data sets as determined by 
Unigene ID. We expect that there is correlation 
between the genes within the CSR signature and 
thus the loss of some genes from this signature will 
be tolerable. 
The most dramatic decrease in CSR genes avail-
able for the analysis was for the Beer et al. (2002) 
lung samples which measured only 32.6% of the 
484 Unigene mapped CSR genes; see Table 1. It 
is possible that the high observed percentage of 
unclassiﬁ  ed samples, 51.2%, is related to this 
diminished in vitro signature. Also, notice that in 
Figure 3c, that the mapping of the in vitro samples 
into the reduced space appears to have ﬂ  ipped 
about horizontal axis from what we saw for the 
other two in vivo data sets. Since the reduced space 
is determined by the in vitro data we expect that 
this inversion is a result of the diminished in vitro 
signature. However, this inversion does not affect 
the association of the classiﬁ  cation with prognosis. 
As shown in Figure 4c the serum induced class has 
Table 2. Cox regression was run on the samples that were classiﬁ  ed as serum induced or serum independent 
by the CSR gene signature. Unclassiﬁ  ed samples are excluded from this analysis. The hazard ratios are relative 
to the serum independent classiﬁ  cation.
 Number  Classiﬁ  ed 
 Serum    Serum  Percent  Hazard  χ
2 Test  p-value  Empirical
 Induced  Independent  Unclassiﬁ  ed  Ratio  Statistic    p-value
Prostate 
Cancer   78  83  45.4%  3.35 20.9 <0.0001  0.0040 
Samples  
Breast 
Cancer  27  27  30.8%  2.96 4.80 0.0284 0.0783 
Samples  
Lung 
Cancer  18  24  51.2%  3.40 3.94 0.0471 0.0111 
Samples  Cancer Informatics 2007:3 241
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Figure 5. The Cox regression test statistic plotted against the percentage of unclassiﬁ  ed samples for each of  the 1000 permutations. The 
circle ﬁ  lled in red denotes the original classiﬁ  cation. A test statistic listed as ‘NA’ indicates that the samples were classiﬁ  ed into only one 
class and thus no test statistic could be calculated. The empirical p-value from the chi-squared statistics is depicted as a histogram in the 
left margin. (A) Glinksy et al. (2004) prostate tumor samples. P < 0.0001; (B) van’t Veer et al. (2002) breast tumor samples, p = 0.0783; (C) 
Beer et al. (2002) lung tumor samples, p = 0.0111.Cancer Informatics 2007:3 242
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worse overall survival than the serum independent 
class, as expected. This change in the reduced space 
mapping highlights the necessity to calculate the 
TSI classifier independently for each in vivo 
dataset, or particularly for each different array 
platform and conﬁ  guration used by the in vivo 
experiments.
Permutation plots provide a complete 
view of the null distribution
Finally, we turn our attention to the permutation 
testing depicted in Figure 5. These three plots carry 
a lot of interesting information regarding the utility 
of the CSR gene signature as a predictor of survival 
among the three tumor types. First, consider the 
horizontal axes of Figures 5a-c. It is intriguing that 
for all three tumor types the CSR signature has the 
lowest percentage of unclassiﬁ  ed samples. Yet we 
see that percentage of classiﬁ  ed samples is not the 
sole predictor of significant separation in the 
survival curves since there are randomly selected 
gene sets that have higher percentages of unclas-
siﬁ  ed samples but also have higher test statistics. 
Next, consider the empirical p-value for testing 
H0
class. In the prostate samples, Figure 5a, the 
empirical p-value is 0.0040, whereas the p-value 
obtained from a simple training/testing strategy is 
very small (chi-squared test statistic = 20.89, 
p < 0.0001). In fact from the scale on the vertical 
axis we see that most of the random permutation 
samples were able to predict a signiﬁ  cant separation 
in the survival of the prostate cancer patients. Thus 
had we relied only on the training/testing strategy 
we could not distinguish that the CSR signature is 
superior to 99.6% of the randomly selected signa-
tures. The range of scale of the test statistics for the 
breast cancer and lung cancer samples are less 
dramatic. In fact the empirical p-value for the lung 
cancer dataset behaves we would normally expect, 
showing that a minimally signiﬁ  cant test statistic in 
the training/testing setting (p = 0.0352) is indeed 
superior to test statistics generated under the clas-
siﬁ  cation null hypothesis (empirical p = 0.0111). 
Conclusions
Further thoughts on hypothesis 
testing
Here we have discussed the nature of hypothesis 
testing when integrating gene expression signa-
tures derived from hypothesis driven in vitro 
studies with gene expression proﬁ  les of in vivo 
tumor samples. Assigning signiﬁ  cance to classiﬁ  -
cation results and associations is necessary to 
evaluate the utility of the in vitro signature in 
cancer development and progression as found in 
vivo. However, for accurate assessment of signif-
icance it is necessary to consider the underlying 
null hypothesis that is being tested. Though the 
permutation test has been widely accepted as a 
panacea for signiﬁ  cance testing we discussed how 
the permutation must be done with care so that the 
underlying null distribution is appropriately recon-
structed. We provide a method of assessing the 
classiﬁ  cation potential of an in vitro signature using 
the TSI classiﬁ  er of Sandberg and Ernberg (2005). 
The classiﬁ  cation null hypothesis underlies tests 
of this classiﬁ  er and thus permutation sampling is 
available for construction of the null distribution 
of test statistics. 
Although we have discussed the value of a well 
deﬁ  ned null hypothesis, the interpretation of the 
alternative hypothesis comes into play when the 
null is rejected. In particular, the alternative 
hypothesis for the classiﬁ  cation null hypothesis is 
that at least one predictive signature exists. The 
number of such signatures is not known and thus 
the signature being tested need not be unique. We 
know from Fan et al. (2006) that there are likely 
to be several predictive signatures in any gene 
expression study. These may be biologically 
similar but need not share a substantial number of 
genes. Rejection of the classiﬁ  cation null hypoth-
esis only provides evidence for the existence of 
one or more predictive signatures. In fact a signif-
icant empirical p-value suggests only superiority 
of the in vitro gene list above the randomly gener-
ated gene lists of comparable size. If other in vitro 
hypotheses were tested the gene signatures gener-
ated may also be predictive. Yet, we argue that 
regardless of its uniqueness, any gene signature 
that rejects the classiﬁ  cation null hypothesis is 
worthy of further study of its biological rele-
vance. 
Further thoughts on thresholding
We have remarked at several points about the use 
of thresholding in the algorithms. Arbitrary thresh-
olds used to select genes that are interesting 
biologically or signatures that are signiﬁ  cant statis-
tically may not always be satisfying. We brieﬂ  y Cancer Informatics 2007:3 243
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discussed how the concept of GSEA could be 
adapted to a regression model that would not 
require a strict deﬁ  nition of the in vitro gene set of 
interest. Yet, the TSI-type algorithm that we 
proposed still used thresholding of the in vitro data 
to produce a signature. This is not necessary for 
the sake of the algorithm and classiﬁ  cation should 
still be possible using the entire gene signature of 
the in vitro samples. Ultimately the classiﬁ  er is 
built on the correlation of the in vivo samples to 
composite signatures for each experimental condi-
tion in the reduced space.
We again used thresholding in the classiﬁ  cation 
of the in vivo samples by requiring a signiﬁ  cant 
correlation with one of the experimental centroids. 
The threshold for signiﬁ  cance was left at the typical 
level of p < 0.05, although this could be adjusted 
to achieve desired speciﬁ  city and sensitivity in the 
classiﬁ  er by dividing the in vivo samples into 
training and test sets and examining various thresh-
olds. Alternatively, the correlation score could be 
used as a continuous variable in the Cox regression 
models. In this way those samples that were not 
classiﬁ  ed in the dichotomous classiﬁ  cation would 
contribute to the model. 
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